Literature DB >> 5045909

Clinical response and serum gold levels in chrysotherapy. Lack of correlation.

R C Gerber, H E Paulus, R Bluestone, C M Pearson.   

Abstract

Mesh：

Substances：

Year:  1972        PMID： 5045909      PMCID： PMC1005931          DOI： 10.1136/ard.31.4.308

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  6 in total

1.  Distribution and excretion of radiogold in animals.

Authors:  M R JEFFREY; H F FREUNDLICH; D M BALLEY
Journal:  Ann Rheum Dis       Date:  1958-03       Impact factor: 19.103

2.  Increasing the effectiveness of gold therapy in rheumatoid arthritis.

Authors:  R T SMITH; W P PEAK; K M KRON; I F HERMANN; R A DELTORO; M GOLDMAN
Journal:  J Am Med Assoc       Date:  1958-07-05

3.  METABOLISM, TOXICITY AND MANNER OF ACTION OF GOLD COMPOUNDS USED IN THE TREATMENT OF ARTHRITIS. I. HUMAN PLASMA AND SYNOVIAL FLUID CONCENTRATION AND URINARY EXCRETION OF GOLD DURING AND FOLLOWING TREATMENT WITH GOLD SODIUM THIOMALATE, GOLD SODIUM THIOSULFATE, AND COLLOIDAL GOLD SULFIDE.

Authors:  R H Freyberg; W D Block; S Levey
Journal:  J Clin Invest       Date:  1941-07       Impact factor: 14.808

4.  Gold determination in biological fluids by atomic absorption spectrophotometry: application to chrysotherapy in rheumatoid arthritis patients.

Authors:  A Lorber; R L Cohen; C C Chang; H E Anderson
Journal:  Arthritis Rheum       Date:  1968-04

5.  Plasma levels and urinary excretion of gold during routine treatment of rheumatoid arthritis.

Authors:  F E Krusius; A Markkanen; P Peltola
Journal:  Ann Rheum Dis       Date:  1970-05       Impact factor: 19.103

6.  Gold excretion in rheumatoid arthritis.

Authors:  R A Jones; M U Ahmed; B W Chan
Journal:  Br Med J       Date:  1971-03-13
  6 in total
  19 in total

1.  Distribution of gold among plasma fractions in rheumatoid patients undergoing chrysotherapy compared with its distribution in plasma incubated with aurothiomalate in vitro.

Authors:  C J Danpure; D A Fyfe; J M Gumpel
Journal:  Ann Rheum Dis       Date:  1979-08       Impact factor: 19.103

2.  Binding of sodium aurothiomalate to human serum albumin in vitro at physiological conditions.

Authors:  S M Pedersen
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

3.  Thiol-containing compounds inhibit the production of monocyte/macrophage-derived angiogenic activity.

Authors:  A E Koch; J C Burrows; P J Polverini; M Cho; S J Leibovich
Journal:  Agents Actions       Date:  1991-11

Review 4.  Clinical pharmacokinetics of oral and injectable gold compounds.

Authors:  K L Blocka; H E Paulus; D E Furst
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

5.  Serum gold concentrations during treatment with auranofin.

Authors:  P L Van Riel; F W Gribnau; L B Van de Putte; C W Arts; A Van Aernsbergen
Journal:  Clin Rheumatol       Date:  1987-03       Impact factor: 2.980

6.  Blood gold concentrations in children with juvenile rheumatoid arthritis undergoing long-term oral gold therapy.

Authors:  E H Giannini; E J Brewer; D A Person
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

7.  Free thiomalate levels in patients with rheumatoid arthritis treated with disodium aurothiomalate: relationship to clinical outcome of therapy.

Authors:  S R Rudge; D Perrett; A J Swannell
Journal:  Ann Rheum Dis       Date:  1984-10       Impact factor: 19.103

8.  Immunomodulatory effects of therapeutic gold compounds. Gold sodium thiomalate inhibits the activity of T cell protein kinase C.

Authors:  K Hashimoto; C E Whitehurst; T Matsubara; K Hirohata; P E Lipsky
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

9.  Auranofin. New oral gold compound for treatment of rheumatoid arthritis.

Authors:  A E Finkelstein; D T Walz; V Batista; M Mizraji; F Roisman; A Misher
Journal:  Ann Rheum Dis       Date:  1976-06       Impact factor: 19.103

10.  Inhibition of antigen- and mitogen-induced human lymphocyte proliferation by gold compounds.

Authors:  P E Lipsky; M Ziff
Journal:  J Clin Invest       Date:  1977-03       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.